In which paediatric age range has the safety and efficacy of Tasigna (nilotinib) been established for Philadelphia chromosome-positive chronic-phase CML?

Tasigna (nilotinib) has established safety and efficacy for Philadelphia chromosome-positive chronic-phase CML from age 2 to under 18 years, although there are no data in newly diagnosed children under 10 and limited data in imatinib-resistant or intolerant children under 6.